Context Therapeutics Inc. · NASDAQ:CNTX
Context Therapeutics — Investor Presentation (January 2026)
40 slides from Context Therapeutics's investor presentation, Jan 8, 2026
Slide 1: Corporate Presentation: Advancing T Cell Engagers for Solid Tumors
January 2026 Corporate Presentation Advancing T Cell Engagers for Solid Tumors
Slide 2: Important Notice and Disclaimers
Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and is subject to risks, uncertainties, assumptions and changes in circumstances
Slide 3: Building a Leading T cell Engager (TCE) Pipeline
Building a Leading T cell Engager (TCE) Pipeline Executive Summary Context Therapeutics Inc. - January 20263 Strategy Developing potentially best-in-class TCE for solid tumors • Tumor antigens that are clinically validated by antibody drug conjugates (ADC) or chimeric antigen receptor T cell therapy
Slide 4: Pipeline Overview
Executive Summary Pipeline Overview Context Therapeutics Inc. - January 20264 PROGRAM TARGET ADDRESSABLE MARKET (U.S. ONLY) DISCOVERY DEVELOPMENT PHASE 1 PHASE 2 ANTICIPATED MILESTONES CTIM-76 Claudin 6 (CLDN6) > 50,000 patients Updated interim Ph 1a data and Ph 1b dose selection Q2 2026 CT-95 Mesot
Slide 5: Positioned to Develop the Next Generation of Transformative T Cell Engagers
Context is Positioned to Develop the Next Generation of Transformative T Cell Engagers Potential to expand into early treatment lines through synergistic drug combinations Executive Summary Context Therapeutics Inc. - January 20265 Synergistic Combination ApproachesOptimized Novel Monotherapies CTIM
Slide 6: T Cell Engager Strategy
T Cell Engager Strategy Context Therapeut ics Inc . - January 20266
Slide 7: T Cell Engaging (TCE) Bispecific Antibodies
T Cell Engaging (TCE) Bispecific Antibodies T Cell Engager Strategy Context Therapeutics Inc. - January 20267 Mechanism of Action T-cell engagers (TCEs) are bispecific antibodies designed to redirect cytotoxic T lymphocytes toward malignant cells. These molecules simultaneously bind to a tumor-assoc
Slide 8: TCE are Highly Differentiated Oncology Products
TCE are Highly Differentiated Oncology Products T Cell Engager Strategy Context Therapeutics Inc. - January 20268 Potency Patient Accessibility TCE ADC Radiotherapy CAR-T TCE Advantages Potent and targeted cytotoxicity against cancer cells Precise dosing and scheduling to fine tune efficacy and safe
Slide 9: FDA Approvals for TCE for Solid and Liquid Tumors
10 FDA Approvals for TCE for Solid and Liquid Tumors Recently approved TCE have had strong initial commercial launches T Cell Engager Strategy Context Therapeutics Inc. - January 20269 2024202320222014 2025 Product Target 2024 Revenue1 Blincyto CD19 x CD3 $1,220 million Tecvayli BCMA x CD3 $549 mill
Slide 10: TCE Success in Solid Tumors
TCE Success in Solid Tumors Asset Tarlatamab (AMG757) HPN328 QLS31905 IBI389 JANX007 JNJ-78278343 Xaluritamig (AMG509) Ubamatamab (REGN4018) Target x Effector DLL3 x CD3 DLL3 x CD3 CLDN18.2 x CD3 CLDN18.2 x CD3 PSMA x CD3 KLK2 x CD3 STEAP1 x CD3 MUC16 x CD3 Cancer Indication Small Cell Lung Small Ce
Slide 11: TCE Success in Solid Tumors Correlated With Potent T Cell Activation
TCE Success in Solid Tumors is Often Correlated With Potent T Cell Activation HPN328, JANX007, and Imdelltra all incorporate high affinity CD3, the most potent T cell activator T Cell Engager Strategy Context Therapeutics Inc. - January 202611 $680M ACQUISITION Confirmed response rate of 35% (11/31)
Slide 12: CTIM-76 CLDN6 x CD3 bispecific antibody
CTIM-76 CLDN6 x CD3 bispecific antibody Context Therapeut ics Inc . - January 202612
Slide 13: CLDN6 Therapies Have the Potential to Reach a Large Patient Population
CLDN6 Therapies Have the Potential to Reach a Large Patient Population >50,000 patients per year in the United States in Relapse/Refractory (R/R) Setting CTIM-76 Program 13 Context Therapeutics Inc. - January 2026 Initial indications of interest based on: • CLDN6 prevalence • Patient population size
Slide 14: CLDN6 is an Attractive Target for Immunotherapy
CLDN6 is an Attractive Target for Immunotherapy • CLDN6 is an oncofetal protein. Normally present at higher levels during embryonic development • Turned off or have low levels of expression in adult tissues • Expression increases with cancer disease stage • Tetraspan protein; does not readily intern
Slide 15: CLDN6 Target Validation
CLDN6 Target Validation CTIM-76 is designed to potentially address limitations of TORL-1-23 (ADC) and BNT211 (CAR-T) CTIM-76 Program Context Therapeutics Inc. - January 202615 CTIM-76 Addresses Limitations of ADC and CAR-THigh Response Rates with CLDN6 ADC and CAR-T CTIM-76 BNT2111 TORL-1-232,3 High
Slide 16: CTIM-76: Claudin x CD3 T cell Engaging Bispecific Antibody
CTIM-76: Claudin 6 x CD3 T cell Engaging (TCE) Bispecific Antibody Optimized structure for CLDN6 selectivity, potency, and manufacturability • Highly selective CLDN6 binding fragment antibody-binding (Fab) arm • Immunostimulatory CD3 binding single-chain fragment variable (scFv) domain is functional
Slide 17: CTIM-76 is a Highly Selective and Potent CLDN6 x CD3 Bispecific Antibody
CTIM-76 Program CTIM-76 is a Highly Selective and Potent CLDN6 x CD3 Bispecific Antibody Context Therapeutics Inc. - January 202617 Selectivity Potency In Vivo Efficacy • CTIM-76 CLDN6 EC50 of 3.41 nM (binding) • CTIM-76 preferentially binds to CLDN6 over CLDN3/4/9 • CLDN3/4/6/9 were transiently tra
Slide 18: CTIM-76 Phase 1a/b Study
CTIM-76 Phase 1a/b Study An open-label, multi-center, dose escalation / expansion, safety, and PK study (NCT06515613) CTIM-76 Program 18 Context Therapeutics Inc. - January 2026 22.5 70 µg 70 140 µg 140 280 µg 140 560 µg TBD 1,120 µg If required If required Cohort 1 Cohort 2 Cohort 3 Cohor
Slide 19: Summary of Preliminary Data from Ongoing Phase 1a Trial of CTIM-76
Summary of Preliminary Data from Ongoing Phase 1a Trial of CTIM-76 as of October 2025 Context anticipates providing updated Phase 1a data and Phase 1b dose selection in the second quarter of 2026 CTIM-76 Program Context Therapeutics Inc. - January 202619 12 patients enrolled: ovarian (7); testicular
Slide 20: CTIM-76 Clinical Competitor Programs Comparison
Clinical Programs Discontinued CTIM-76 XmAb541 ARC101 BGB-B455 AMG794 SAIL66 Company Context Xencor Third Arc BeOne Amgen Chugai Stage Ph 1 Ph 1 Ph 1 Ph 1 Ph 11 Ph 1 Bispecific Format 1 + 1 2 + 1 1 + 1 1 + 1 HLE Bite Dual Specific Fab CLDN3/4 Selectivity High1 Moderate2 High3 Not Disclosed4 High6 Mo
Slide 21: CT-95 MSLN x CD3 bispecific antibody
CT-95 MSLN x CD3 bispecific antibody Context Therapeut ics Inc . - January 202621
Slide 22: MSLN Therapies Have the Potential to Reach a Large Patient Population
MSLN Therapies Have the Potential to Reach a Large Patient Population >100,000 patients per year in the United States in Relapse/Refractory (R/R) Setting CT-95 Program 22 Context Therapeutics Inc. - January 2026 Selected Cancer indications Incidence (US Only) R/R Incidence MSLN Positive MSLN Med/Hig
Slide 23: MSLN Target Biology
MSLN Target Biology Shed mesothelin (sMSLN) in tumor microenvironment requires a creative solution to overcome CT-95 Program Context Therapeutics Inc. - January 202623 MSLN is bound to tumor cells via a GPI-anchor Like many GPI-anchored proteins, MSLN can be cut into smaller fragments1,2 The MSLN ge
Slide 24: CT-95: MSLN x CD3 T cell Engaging Bispecific Antibody
CT-95: MSLN x CD3 T cell Engaging (TCE) Bispecific Antibody Novel design to overcome mesothelin (MSLN) sink • Binds to membrane-proximal MSLN epitope • Affinity tuned MSLN binding • Cooperative binding results in high affinity binding of CT-95 to tumor Potentially wide therapeutic window • No crossl
Slide 25: Two-Pronged Approach to Overcoming Soluble MSLN Sink Challenge
Two-Pronged Approach to Overcoming Soluble MSLN Sink Challenge CT-95 Program 25 Binds MSLN Epitope Close to Cell Surface Activates T cells Through Cooperative Binding + CD3 Potent T cell activationNo T cell activation No crosslinking with shed MSLN MSLN on tumor crosslinks CD3Far From cell surface C
Slide 26: Cytotoxicity in the Presence of Soluble MSLN
Cytotoxicity in the Presence of Soluble MSLN CT-95 Intended to Overcome MSLN Sink HPN-536 (Harpoon Therapeutics) binds to soluble MSLN (sMSLN) in a dose proportional manner, limiting therapeutic exposure CT-95 Program Context Therapeutics Inc. - January 202626 CT-95 +10nM sMSLN +30nM sMSLN HPN-536 +
Slide 27: CT-95 is Highly Active and Well Tolerated Across In Vivo Models
CT-95 is Highly Active and Well Tolerated Across In Vivo Models Complete tumor regressions in mice at doses ≤ 0.05 mg/kg CT-95 Program Context Therapeutics Inc. - January 202627 Primary Lesion Model Metastatic Lesion Model OVCAR3 pre-passaged in mice to generate aggressive, metastatic tumor model Ov
Slide 28: CT-95 Phase 1a/b Study
CT-95 Phase 1a/b Study An open-label, multi-center, dose escalation / expansion, safety, and PK study (NCT06756035) CT-95 Program 28 Context Therapeutics Inc. - January 2026 Trial status information provided as of January 5, 2026 0.3 µg/kg 0.18 0.6 µg/kg 0.27 0.9 µg/kg 0.36 1.2 µg/kg 0.48 1.
Slide 29: CT-95 Competitive Landscape
CT-95 Competitive Landscape CT-95 is avidity enhanced, affinity tuned, and binds to membrane-bound MSLN CT-95 Program Context Therapeutics Inc. - January 202629 CT-95 AMG-305 HPN-536 JNJ-79032421 ZW171 Company Context Amgen4 Harpoon1 JNJ Zymeworks2,3 Format 2 + 2 1 + 1 + 2 CDH3 + MSLN dBiTE TriTAC 1
Slide 30: CT-202 Nectin-4 x CD3 bispecific antibody
CT-202 Nectin-4 x CD3 bispecific antibody Context Therapeut ics Inc . - January 202630
Slide 31: Nectin-4 Therapies Have the Potential to Reach a Large Patient Population
Nectin-4 Therapies Have the Potential to Reach a Large Patient Population >125,000 patients per year in the United States in Relapse/Refractory (R/R) Setting CT-202 Program 31 Context Therapeutics Inc. - January 2026 Selected Cancer indications Incidence (US Only) R/R Incidence Nectin-4 Positive Nec
Slide 32: CT-202: Nectin-4 x CD3 T cell Engaging Bispecific Antibody
CT-202: Nectin-4 x CD3 T cell Engaging (TCE) Bispecific Antibody CT-202 Program Context Therapeutics Inc. - January 202632 α-Nectin-4 Fab α-CD3 scFv IgG1 backbone Silenced Fc Novel design incorporating logic gating to spare Nectin-4 in normal tissue • Because of its expression in healthy epidermal k
Slide 33: Two-Pronged Approach to Overcoming Nectin-4 Expression in Skin
Two-Pronged Approach to Overcoming Nectin-4 Expression in Skin CT-202 Program 33 Logic Gating Through pH Dependency + Increased Target Selectivity Through Avidity 1 Chang, PNAS, 2021 CD3 Potent T cell activationNo T cell activation High on-/off-rate when bound to Nectin-4 monomer Avidity-enhanced Ne
Slide 34: CT-202 is Highly Active and Well Tolerated Across In Vivo Models
CT-202 is Highly Active and Well Tolerated Across In Vivo Models CT-202 Program Context Therapeutics Inc. - January 202634 Complete Tumor Regressions CT-202 demonstrated similar efficacy in BT474 breast cancer xenograft compared to enfortumab TCE control antibodies in mice Reduced Cytokine Release C
Slide 35: CT-202 Competitive Landscape
CT-202 Competitive Landscape Competitor TCE programs lack conditional activation, avidity enhancement, and high potency immune activator Context Therapeutics Inc. - January 202635 Company Context Therapeutics Bicycle Therapeutics Rondo Therapeutics Asset CT-202 BT74801,2 RNDO-5643 Format 2 + 2 (pH d
Slide 36: Corporate
Corporate 36 Context Therapeut ics Inc . - January 2026
Slide 37: Experienced Leadership Team
Corporate Experienced Leadership Team • Experienced management team • Clinical team has developed T cell therapies • Our management team is supported by a Board with deep oncology experience Focus on Execution Martin Lehr CEO and Director Alex Levit, Esq Chief Legal Officer Karen Chagin, MD Chief Me
Slide 38: Investment Highlights
Corporate Investment Highlights (Nasdaq: CNTX) Solid Tumors + ADC Resistance Large Unmet Need Claudin 6 + Mesothelin + Nectin-4 High-Value Targets CTIM-76 interim Ph 1a data update + Ph 1b dose selection Q2 2026 CT-95 initial Ph 1a data Mid 2026 CT-202 Submit regulatory filings for FIH trial Q2 2026
Slide 39: Advancing T Cell Engagers for Solid Tumors
Advancing T Cell Engagers for Solid Tumors © Context Therapeutics 2026
Slide 40: Glossary
Glossary ADC Antibody drug conjugate AE Adverse event CAR-T Chimeric antigen receptor T cell therapy CD3 Cluster of differentiation 3 CLDN Claudin CRS Cytokine release syndrome DLT Dose limiting toxicity Fab Fragment antigen-binding region FIH First-in-human FRα Folate receptor alpha GPI Glycosylpho
Context Therapeutics — Investor Presentation (January 2026) on 6ix